Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease

Background Hyperuricemia is a leading risk factor for the development of chronic kidney disease (CKD). We hypothesized that lowering serum uric acid (SUA) with allopurinol in hyperuricemic children with CKD may reduce the risk of CKD progression. Methods A total of 70 children, aged 3–15 years, with...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric nephrology (Berlin, West) West), 2018-08, Vol.33 (8), p.1405-1409
Main Authors: Ghane Sharbaf, Fatemeh, Assadi, Farahnak
Format: Article
Language:English
Subjects:
Allopurinol
Blood pressure
Body mass index
C-reactive protein
Children
Childrens health
Chronic illnesses
Chronic kidney failure
Complications and side effects
Development and progression
Dosage and administration
Drug therapy
Epidermal growth factor receptors
Glomerular filtration rate
Hyperuricemia
Kidney diseases
Kidneys
Medical examination
Medicine
Medicine & Public Health
Multiple regression analysis
Nephrology
Original Article
Patients
Pediatrics
Renal function
Risk factors
Uric acid
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hyperuricemia is a leading risk factor for the development of chronic kidney disease (CKD). We hypothesized that lowering serum uric acid (SUA) with allopurinol in hyperuricemic children with CKD may reduce the risk of CKD progression. Methods A total of 70 children, aged 3–15 years, with elevated serum uric acid level (SUA) > 5.5 mg/dL and CKD stages 1–3 were prospectively randomized to receive allopurinol 5 mg/kg/day (study group, n  = 38) or no treatment (control group, n  = 32) for 4 months. The primary and secondary outcomes were changes in estimated glomerular filtration rate (eGFR) (> 10 mL/min/1.73m 2 ) and the SUA (> 1.0 mg/dL) from baseline values, respectively. Results Baseline age, gender, blood pressure (BP), body mass index (BMI), SUA, high-sensitive C-reactive protein (hsCRP), and eGFR were similar in allopurinol and control subjects. Allopurinol treatment resulted in a decrease in SUA, a decrease in systolic and diastolic BP, a decrease in hsCRP, and an increase in eGFR compared with the baseline values ( p  
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-018-3943-1